Inhibition of PI3Kγ appears to sensitize tumors to anti-PD-1 antibody therapy and to slow tumor growth by increasing the level of CD4+ and CD8+ T lymphocytes within the tumor [131]. The gene discussed is CD8A; the disease is neoplasm.